New Publication Reviews GLP-1 Agonist-Induced Gastroparesis, Including Exenatide

A systematic review titled "Gastroparesis induced by glucagon-like peptide-1 receptor agonists: A systematic review of clinical features, diagnosis, management, and outcomes" was published on August 13, 2026. The publication appeared in the journal PloS one. Exenatide is among the GLP-1 receptor agonists discussed in the review's title and scope. The publication is listed as a systematic review, indicating it compiles and evaluates existing literature on this topic. According to the available data, the review covers clinical features, diagnosis, management, and outcomes related to gastroparesis associated with this drug class. No specific findings, statistics, or conclusions from the review are provided in the source data. This brief does not summarize or interpret the review's results beyond confirming its publication and stated scope. Readers interested in the full findings should consult the original publication directly through the provided source link. For additional background on exenatide, including its approved regulatory status and general information, readers can refer to the compound overview.